Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Free Cash Flow (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Free Cash Flow for 13 consecutive years, with $578000.0 as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 93.21% to $578000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.2 million through Dec 2025, up 10.6% year-over-year, with the annual reading at $13.2 million for FY2025, 10.6% up from the prior year.
  • Free Cash Flow for Q4 2025 was $578000.0 at Niagen Bioscience, down from $3.7 million in the prior quarter.
  • The five-year high for Free Cash Flow was $8.5 million in Q4 2024, with the low at -$8.2 million in Q2 2021.
  • Average Free Cash Flow over 5 years is -$393850.0, with a median of $312000.0 recorded in 2023.
  • The sharpest move saw Free Cash Flow plummeted 1886.35% in 2021, then soared 2990.94% in 2025.
  • Over 5 years, Free Cash Flow stood at -$4.9 million in 2021, then skyrocketed by 89.89% to -$500000.0 in 2022, then surged by 225.6% to $628000.0 in 2023, then soared by 1255.73% to $8.5 million in 2024, then plummeted by 93.21% to $578000.0 in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $578000.0, $3.7 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.